Aquestive Therapeutics, Inc. (AQST) on GreekSoup https://greeksoup.ai/stocks/us/aqst/ Every dated entry in the public record on Aquestive Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Fri, 30 Oct 2026 00:00:00 +0000 Aquestive Therapeutics, Inc. filed 8-K: charter or bylaw amendment, or fiscal year changehttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-10-19:1c2a90cfd7Mon, 19 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Barber Daniel (President and CEO) sold 25,000 shares (under a trading plan set in advance) at $4.22 on 15 October 2026, $105,600https://greeksoup.ai/stocks/us/aqst/insiders/us:AQST:insider:2026-10-16:5898b3187aFri, 16 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: regulation fd disclosurehttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-10-15:b3f13d1ba3Thu, 15 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: short interest 27,597,742 shares at the 15 October 2026 settlement, 13.88 days to coverhttps://greeksoup.ai/stocks/us/aqst/short-interest/us:AQST:short-interest:2026-10-15:0dc1f3ed11Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: material agreementhttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-10-14:a000a3b86dWed, 14 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Schedule 13G filed by Bass Edward P, 7.5% of the classhttps://greeksoup.ai/stocks/us/aqst/holders/us:AQST:schedule-13:2026-10-07:8ff9cfa690Wed, 07 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Schedule 13G/A filed by BRATTON DOUGLAS K, 0.6% of the classhttps://greeksoup.ai/stocks/us/aqst/holders/us:AQST:schedule-13:2026-10-07:7fe549ee93Wed, 07 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: short interest 28,748,212 shares at the 30 September 2026 settlement, 13.06 days to coverhttps://greeksoup.ai/stocks/us/aqst/short-interest/us:AQST:short-interest:2026-09-30:5d0caa48deWed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: officer or director changehttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-09-29:fa22d25f3aTue, 29 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: regulation fd disclosurehttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-09-25:29e97712f9Fri, 25 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-09-17:c7f13722b1Thu, 17 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Barber Daniel (President and CEO) sold 25,000 shares (under a trading plan set in advance) at $4.82 on 15 September 2026, $120,487https://greeksoup.ai/stocks/us/aqst/insiders/us:AQST:insider:2026-09-16:de32e433f8Wed, 16 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Form 144, Daniel Barber plans to sell 50,000 shares worth $244,000 around 15 September 2026https://greeksoup.ai/stocks/us/aqst/planned-sales/us:AQST:planned-sale:2026-09-15:9094c402e3Tue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: short interest 27,161,738 shares at the 15 September 2026 settlement, 11.81 days to coverhttps://greeksoup.ai/stocks/us/aqst/short-interest/us:AQST:short-interest:2026-09-15:20472c9b6dTue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Korczynski Sherry (Chief Commercial Officer) sold 8,750 shares (under a trading plan set in advance) at $5.22 on 9 September 2026, $45,675https://greeksoup.ai/stocks/us/aqst/insiders/us:AQST:insider:2026-09-11:86f81026b0Fri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Form 144, Sherry M. Korczynski plans to sell 8,750 shares worth $45,588 around 9 September 2026https://greeksoup.ai/stocks/us/aqst/planned-sales/us:AQST:planned-sale:2026-09-09:2379ad7b66Wed, 09 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: short interest 25,478,782 shares at the 31 August 2026 settlement, 7.15 days to coverhttps://greeksoup.ai/stocks/us/aqst/short-interest/us:AQST:short-interest:2026-08-31:abad1ebe61Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Barber Daniel (President and CEO) sold 25,000 shares (under a trading plan set in advance) at $4.29 on 17 August 2026, $107,168https://greeksoup.ai/stocks/us/aqst/insiders/us:AQST:insider:2026-08-18:ca6d4e5a05Tue, 18 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: Form 144, Daniel Barber plans to sell 25,000 shares worth $106,250 around 17 August 2026https://greeksoup.ai/stocks/us/aqst/planned-sales/us:AQST:planned-sale:2026-08-17:f1d1946257Mon, 17 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc.: short interest 20,951,747 shares at the 14 August 2026 settlement, 5.19 days to coverhttps://greeksoup.ai/stocks/us/aqst/short-interest/us:AQST:short-interest:2026-08-14:9bf3ce8eb2Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. Q2 FY2026 results: revenue $14 million, net income -$23 millionhttps://greeksoup.ai/stocks/us/aqst/results/fy2026-q2/us:AQST:result:2026-08-11:f570428dbbTue, 11 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-08-11:9e1d5b2e58Tue, 11 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: results of operations, regulation fd disclosurehttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-08-11:20deb18918Tue, 11 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aquestive Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/aqst/filings/us:AQST:filing:2026-08-10:d27ec7da79Mon, 10 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]>